David Jackson
Chief Executive Officer Ceria Therapeutics
David Jackson is a seasoned executive and board member with over 25 years of leadership in the life sciences and biotechnology sectors. He currently serves as the CEO of Ceria Therapeutics and is a dedicated Board Member for the Project 8p Foundation, a non-profit focused on a rare chromosomal disorder. With a deep background in personalized medicine, companion diagnostics, and corporate strategy, David brings a wealth of experience in guiding companies from early development through to commercialization.
Seminars
The breakthroughs in RNAi delivery are no longer confined to the liver, with a new generation of platforms, from antibody conjugates and DNA nanostructures to novel ligands and chemical modifications, enabling precise targeting of metabolic, muscular, and renal tissues. This roundtable unites pioneers to discuss:
- Weighing the advantages of modular platforms against bespoke conjugate strategies for specific tissue targets, considering factors like valency, manufacturability, and immunogenicity.
- Addressing the unique synthesis, characterization, and manufacturing challenges of complex delivery modalities to ensure quality, stability, and scalability for clinical and commercial supply.
- Strategizing on how to design platforms with inherent adaptability to rapidly retarget new tissues and diseases, maximizing platform value and accelerating development timelines.
- n selection for optimal risk/reward, ensuring portfolio companies can attract pharma partnerships or IPO success
The future of RNAi lies at the intersection of precision medicine, AI-driven innovation, and strategic combination approaches. This panel explores how integrating cutting-edge technologies like AI target discovery with synergistic modalities can unlock new therapeutic potential. Experts will discuss multi-target silencing strategies, new target molecule classes, and how to future-proof RNAi pipelines to lead the next wave of transformative treatments. Join us to gain actionable insights on positioning your RNAi therapeutics at the forefront of precision medicine by discussing:
- Exploring AI-driven target discovery and combination therapies with CAR-T or radiotherapy to accelerate identification of disease-specific genes with high clinical relevance to enable faster precision RNAi therapy development
- Predicting future combination therapy strategies to stay ahead of emerging trends in multi-target silencing, for the expansion of treatment options for complex diseases
- Strategizing how to position pipelines at the forefront of next-gen RNAi innovation
- Exploiting a novel RNAi delivery modality due to unique uptake and release kinetics for the development of acute RNAi therapeutics
- Leveraging direct tissue targeting of RNAi therapeutics to unlock previously inaccessible conditions for improved therapeutic outcomes
- Using selective translational models to derisk RNAi therapeutic development for pipeline acceleration
Chemical engineering of RNAi therapeutics is pivotal for expanding their delivery beyond the liver, to tissues like the CNS, muscle, and eye. Attendees will gain insights into optimizing RNAi constructs for improved stability,
potency, and delivery efficiency, bridging the gap between preclinical promise and clinical success. A must-attend for researchers aiming to unlock the full potential of RNAi in extrahepatic applications by discussing:
- Incorporating phosphorothioate and 2-modifications to boost siRNA nuclease resistance, enabling prolonged activity in extrahepatic tissues
- Designing lipid-conjugated siRNAs for enhanced cellular uptake without carriers, simplifying delivery to challenging targets like skeletal muscle or the eye
- Tailoring hydrophobicity and charge to optimize biodistribution and endosomal escape, maximizing target gene knockdown in non-liver organs
